Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253603 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetics of QAW039
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01253603 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 170 participants.
The verdict
NCT01253603, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
Interventions
- DRUG QAW039 capsules once daily for 28 days
- DRUG Placebo to QAW039 capsules once daily for 28 days
- DRUG Fluticasone propionate inhaler twice daily for 28 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253603
The ClinicalTrials.gov registry entry for NCT01253603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which QAW039 capsules once daily for 28 days is the first listed.
NCT01253603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253603 about?
NCT01253603 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of QAW039". This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.
What is the current status of trial NCT01253603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01253603?
The interventions under investigation include: QAW039 capsules once daily for 28 days (DRUG), Placebo to QAW039 capsules once daily for 28 days (DRUG), Fluticasone propionate inhaler twice daily for 28 days (DRUG).
Who is sponsoring clinical trial NCT01253603?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.